|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5985846A
(en)
|
1995-06-07 |
1999-11-16 |
Baylor College Of Medicine |
Gene therapy for muscular dystrophy
|
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
|
WO1998054345A1
(en)
|
1997-05-30 |
1998-12-03 |
Baxter International Inc. |
Mini-adenoviral vector
|
|
WO1999053085A2
(en)
|
1998-04-15 |
1999-10-21 |
The Research Foundation Of State University Of New York |
Selective regulation of adenovirus production
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US5989910A
(en)
|
1998-08-03 |
1999-11-23 |
University Of Lausanne |
Potent genetic switch allowing regulated gene expression in eukaryotic cells
|
|
US6423544B1
(en)
|
1998-12-31 |
2002-07-23 |
Chiron Corporation |
Compositions and methods for producing recombinant virions
|
|
MY123548A
(en)
|
1999-11-08 |
2006-05-31 |
Shell Int Research |
Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
|
ATE440133T1
(de)
|
2001-02-21 |
2009-09-15 |
Cevec Pharmaceuticals Gmbh |
Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
|
|
ES2439874T3
(es)
|
2002-05-29 |
2014-01-27 |
Regeneron Pharmaceuticals, Inc. |
Sistema de expresión en eucariotas inducible
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
WO2005106046A1
(en)
|
2004-05-03 |
2005-11-10 |
Stefan Kochanek |
Modified viral vector particles
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
AU2007249695A1
(en)
|
2006-05-15 |
2007-11-22 |
Paratek Pharmaceuticals, Inc. |
Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
|
|
EP2150617B1
(en)
|
2007-06-04 |
2014-10-22 |
Regeneron Pharmaceuticals, Inc. |
Enhanced expression and stability regions
|
|
US8852926B2
(en)
|
2007-10-25 |
2014-10-07 |
Board Of Trustees Of Southern Illinois University |
Genetic selection system for identification of MicroRNA target genes
|
|
DE102009003439A1
(de)
|
2009-02-05 |
2010-08-26 |
Cevec Pharmaceuticals Gmbh |
Neue permanente humane Zelllinie
|
|
US8734809B2
(en)
*
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2011126808A2
(en)
*
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
US9839696B2
(en)
|
2010-04-30 |
2017-12-12 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
EP2606128B1
(de)
|
2010-08-16 |
2014-09-10 |
CEVEC Pharmaceuticals GmbH |
Permanente humane amniozyten zellinie zur herstellung von influenzaviren
|
|
EP2662451A1
(en)
|
2012-05-07 |
2013-11-13 |
Stefan Kochanek |
Nucleic acid construct and use of the same
|
|
EP2711428A1
(en)
|
2012-09-21 |
2014-03-26 |
Lonza Biologics plc. |
Site-specific integration
|
|
JP6676526B2
(ja)
|
2013-08-06 |
2020-04-08 |
ロンザ バイオロジクス ピーエルシー |
組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
BR112017008022A2
(pt)
|
2014-10-23 |
2018-02-20 |
Regeneron Pharmaceuticals, Inc. |
célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse.
|
|
EP3042952A1
(en)
|
2015-01-07 |
2016-07-13 |
CEVEC Pharmaceuticals GmbH |
O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
EP3205719A1
(en)
|
2016-02-15 |
2017-08-16 |
CEVEC Pharmaceuticals GmbH |
Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
|
|
GB201603577D0
(en)
|
2016-03-01 |
2016-04-13 |
Oxford Genetics Ltd |
Promoter
|
|
WO2017173043A1
(en)
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
SG11201807885PA
(en)
|
2016-04-20 |
2018-10-30 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
WO2018031769A1
(en)
|
2016-08-10 |
2018-02-15 |
Lonza Inc. |
Biopharmaceutical batch recipe review by exception
|
|
WO2018146588A1
(en)
|
2017-02-08 |
2018-08-16 |
Friedrich Miescher Institute For Biomedical Research |
Synp88, a promoter for the specific expression of genes in retinal ganglion cells
|
|
JP7467119B2
(ja)
|
2017-02-17 |
2024-04-15 |
ロンザ リミテッド |
発現困難タンパク質のための多部位ｓｓｉ細胞
|
|
KR102719587B1
(ko)
|
2017-02-17 |
2024-10-17 |
론자 리미티드 |
아데노-관련 바이러스 생산을 위한 포유동물 세포
|
|
CN110419011A
(zh)
|
2017-03-17 |
2019-11-05 |
龙沙有限公司 |
自动化批量数据分析
|
|
WO2018175775A1
(en)
|
2017-03-22 |
2018-09-27 |
Dimension Therapeutics |
Cell culture methods involving hdac inhibitors or rep proteins
|
|
EP3382014A1
(en)
|
2017-03-29 |
2018-10-03 |
CEVEC Pharmaceuticals GmbH |
Recombinant glycoproteins with reduced antennary fucosylation
|
|
GB201705927D0
(en)
|
2017-04-12 |
2017-05-24 |
Oxford Genetics Ltd |
Vector
|
|
EP3612635A2
(en)
|
2017-04-18 |
2020-02-26 |
GlaxoSmithKline Intellectual Property Development Limited |
Methods for adeno-associated viral vector production
|
|
CN110892064A
(zh)
|
2017-07-25 |
2020-03-17 |
牛津遗传学有限公司 |
腺病毒载体
|
|
EP3441471A1
(en)
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
EP3456822A1
(en)
|
2017-09-19 |
2019-03-20 |
CEVEC Pharmaceuticals GmbH |
Inducible aav rep genes
|
|
US12123027B2
(en)
|
2017-10-12 |
2024-10-22 |
Ascend Advanced Therapies Limited |
Life-cycle-defective adenovirus helper viruses, their production and use for producing rAAV
|
|
AU2018356538B2
(en)
|
2017-10-25 |
2023-09-28 |
Nouscom Ag |
Eukaryotic cell line
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
GB201800903D0
(en)
|
2018-01-19 |
2018-03-07 |
Oxford Genetics Ltd |
Vectors
|
|
WO2019157239A1
(en)
|
2018-02-08 |
2019-08-15 |
David Kiewlich |
Plasmid vectors for expression of large nucleic acid transgenes
|
|
GB201802122D0
(en)
|
2018-02-09 |
2018-03-28 |
Univ Oxford Innovation Ltd |
Product and use
|
|
GB201814590D0
(en)
|
2018-09-07 |
2018-10-24 |
Oxford Biomedica Ltd |
Viral vector production system
|
|
EP3597172A1
(en)
|
2018-07-16 |
2020-01-22 |
Kao Germany GmbH |
Hair treatment composition
|
|
EP3833745A1
(en)
*
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
EP3841193A1
(en)
|
2018-08-21 |
2021-06-30 |
Lonza Ltd. |
A process for creating reference data for predicting concentrations of quality attributes
|
|
GB201814141D0
(en)
|
2018-08-30 |
2018-10-17 |
Univ Oxford Innovation Ltd |
Method and compositions for producing a virus
|
|
JP7549582B2
(ja)
|
2018-10-01 |
2024-09-11 |
ロンザ リミテッド |
予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
|
|
AU2019362280B2
(en)
|
2018-10-17 |
2026-03-19 |
Children's Medical Research Institute |
Nucleic acid molecules and methods for AAV vector selection
|
|
GB201816919D0
(en)
|
2018-10-17 |
2018-11-28 |
Glaxosmithkline Ip Dev Ltd |
Adeno-associated viral vector producer cell lines
|
|
WO2020084034A1
(en)
|
2018-10-26 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
|
CN113396222A
(zh)
*
|
2018-12-21 |
2021-09-14 |
隆萨沃克斯维尔股份有限公司 |
腺相关病毒(aav)生产细胞系和相关方法
|
|
KR20210108406A
(ko)
|
2018-12-21 |
2021-09-02 |
론자 워커스빌 아이엔씨. |
바이러스 벡터의 자동화된 생산
|
|
AU2019403279A1
(en)
|
2018-12-21 |
2021-07-01 |
Genentech, Inc. |
Targeted integration of nucleic acids
|
|
GB201901571D0
(en)
|
2019-02-05 |
2019-03-27 |
Oxford Genetics Ltd |
Inducible AAV sysyem
|
|
GB201902068D0
(en)
|
2019-02-14 |
2019-04-03 |
Cambridge Entpr Ltd |
Methods of reactivating proliferative capacity non-proliferative tissues
|
|
CN113544509A
(zh)
|
2019-03-08 |
2021-10-22 |
牛津遗传学有限公司 |
选择抗体的方法
|
|
SG11202110904PA
(en)
|
2019-04-12 |
2021-10-28 |
Ultragenyx Pharmaceutical Inc |
Engineered producer cell lines and methods of making and using the same
|
|
JP7663513B2
(ja)
|
2019-05-16 |
2025-04-16 |
トラスティーズ オブ ボストン ユニバーシティ |
調節された合成遺伝子発現システム
|
|
AU2020284255A1
(en)
|
2019-05-30 |
2022-01-06 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
WO2021127432A1
(en)
|
2019-12-19 |
2021-06-24 |
Lonza Walkersville, Inc. |
Automated production of viral vectors
|
|
CN115315518A
(zh)
|
2020-01-17 |
2022-11-08 |
阿斯克肋匹奥生物制药公司 |
重组aav的生产
|
|
GB202001484D0
(en)
|
2020-02-04 |
2020-03-18 |
Oxford Genetics Ltd |
DNA amplification method
|
|
CN115298316B
(zh)
|
2020-02-04 |
2025-02-14 |
牛津遗传学有限公司 |
用于制备腺相关病毒载体的方法
|
|
US20230235353A1
(en)
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
EP4150097A1
(en)
|
2020-05-15 |
2023-03-22 |
Ivexsol, Inc. |
Compositions and methods for producing stable viral vector producer cells for cell and gene therapy
|
|
CN113699147B
(zh)
|
2020-05-22 |
2023-06-09 |
深圳市深研生物科技有限公司 |
基于四环素和Cumate的共调控序列
|
|
US20230279427A1
(en)
|
2020-07-24 |
2023-09-07 |
Regents Of The University Of Minnesota |
Cell lines for recombinant aav production and aav-implemented protein production
|
|
GB202013060D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Cell line
|
|
GB202013057D0
(en)
|
2020-08-21 |
2020-10-07 |
Oxford Genetics Ltd |
Method of making recombinant aavs
|
|
WO2022038367A1
(en)
|
2020-08-21 |
2022-02-24 |
Oxford Genetics Limited |
Process for making a recombinant aav library
|
|
EP4006141A1
(en)
|
2020-11-25 |
2022-06-01 |
CEVEC Pharmaceuticals GmbH |
Method for the production of aav
|
|
KR20230142712A
(ko)
|
2021-02-11 |
2023-10-11 |
론자 휴스턴, 아이엔씨. |
아데노-연관된 바이러스(aav) 생산
|
|
JP2024517104A
(ja)
|
2021-04-19 |
2024-04-19 |
オックスフォード ジェネティクス リミテッド |
Ｃａｒｅエレメントを用いたｄｎａ増幅方法
|
|
US20230257831A1
(en)
|
2021-09-01 |
2023-08-17 |
Oxford Genetics Limited |
Method for determining aav titre
|
|
CA3235566A1
(en)
|
2021-10-18 |
2023-04-27 |
Michael Goren |
Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
|
|
CN118159660A
(zh)
|
2021-10-18 |
2024-06-07 |
瑞泽恩制药公司 |
多核苷酸的受控转录
|
|
WO2023173105A2
(en)
|
2022-03-10 |
2023-09-14 |
Saliogen Therapeutics, Inc. |
Tetracycline inducer/repressor system and simplified viral particle production
|